SELECTED POSTER PRESENTATIONS
|
|
- Andrea West
- 5 years ago
- Views:
Transcription
1 SELECTED POSTER PRESENTATIONS The following summaries are based on posters presented at the American Urogynecological Society 2004 Scientific Meeting, held July 29-31, 2004, in San Diego, California. CENTRAL NERVOUS SYSTEM EFFECTS WITH TWO ANTICHOLINERGIC MEDICATIONS IN WOMEN WITH OVERACTIVE BLADDER Based on a poster presented by Sand PK,* Luber K, Dmochowski R *Northwestern University Medical School, Evanston, Illinois; Kaiser Permanente Southern California, San Diego, California; Vanderbilt University Medical Center, Nashville, Tennessee between treatment groups (Table). No significant differences were noted between treatment-naive patients and those with a history of treatment with anticholinergic agents. Older patients tended to report more CNS events, but the difference was not significantly different from younger patients or between treatment groups. The Overactive Bladder Performance of Extended- Release Agents (OPERA) trial compared long-acting formulations of the anticholinergic agents oxybutynin and tolterodine in women with symptomatic overactive bladder. Overall, the trial demonstrated similar reductions in urinary incontinence episodes in patients treated with either agent. However, significantly more patients treated with oxybutynin reported achieving total dryness, and they also had a significant reduction in micturition frequency, compared with tolterodine. In vitro studies suggest that anticholinergic medications might cross the blood-brain barrier, which would create a potential for central nervous system (CNS) side effects. The incidence of CNS events was not specifically evaluated in the OPERA trial. A retrospective analysis of data from the trial sought to determine the potential for CNS events with the extended-release formulations of oxybutynin and tolterodine. OPERA was a prospective, randomized, doubleblind, parallel group, multicenter, 12-week study. Participants were evaluated at weeks 2, 4, 8, and 12. The subanalysis describes the incidence of CNS events documented during the trial. The most common adverse event in OPERA was dry mouth, reported by 29.7% of oxybutynin patients and 22.3% of tolterodine patients. Overall, the incidence of CNS side effects was low and similar Table. CNS Events by Treatment Group CNS O T Event (n = 391) (n = 399) Dizziness 10 (2.6%) 7 (1.8%) Somnolence 3 (0.8%) 8 (2.0%) Insomnia 5 (1.3%) 0 Anxiety 3 (0.8%) 2 (0.5%) Tremor 1 (0.25 %) 1 (0.25% CNS = central nervous system; O = oxybutynin; T = tolterodine. Extended-release formulations of oxybutynin and tolterodine were associated with low rates of CNS events in the OPERA trial. No significant differences were noted between treatment-naive and treatmentexperienced patients. S860 Vol. 4 (10C) November 2004
2 URGENCY EPISODES WERE STATISTICALLY SIGNIFICANTLY REDUCED WITH SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER Based on a poster presented by Lucente V,* Swift S *Institute for Female Pelvic Medicine and Reconstructive Surgery, Allentown, Pennsylvania; Medical University of South Carolina, Charleston, South Carolina, for the Solifenacin Study Group Overactive bladder (OAB) affects 17% of women, 40% of whom do not seek medical attention. Almost 75% of affected women remain untreated. Solifenacin, a once-daily oral antimuscarinic agent under development for treatment of OAB, has demonstrated statistically significant reductions in OAB symptoms in multiple clinical trials. Patients treated with solifenacin have experienced reduced episodes of urgency, incontinence, and frequency, which have been associated with low rates of dry mouth, particularly at the 5-mg dose. An analysis of 4 pivotal clinical studies was undertaken to determine the change in the number of urgency episodes per 24 hours in patients treated with solifenacin. All 4 studies had a randomized, placebo-controlled design that permitted evaluation of the safety, efficacy, and tolerability of solifenacin. Symptomatic OAB patients who reported all micturitions per 24 hours and 1 or more incontinence or urgency episodes per 24 hours were enrolled in the studies. The patients were randomized to placebo or to solifenacin 5 mg once daily in 2 of the 4 studies, and the remaining 2 studies evaluated solifenacin 5 mg once daily and solifenacin 10 mg once daily versus placebo. The change in the number of urgency episodes per 24 hours was a secondary efficacy variable in all 4 studies. Efficacy was based on urgency data from micturition diaries completed during the 3 days prior to each monthly patient visit. Two principal analyses were conducted. One analysis focused on the mean and median reductions in the number of urgency episodes per 24 hours from each of the 4 studies. A pooled analysis of the studies employed analysis of covariance with baseline as a covariate to determine overall efficacy from the trials. The analysis included 1124 evaluable patients treated with placebo, 548 treated with solifenacin 5 mg once daily, and 1151 patients treated with solifenacin 10 mg once daily. At baseline, the mean number of urgency episodes was approximately 6 per 24-hour period. Changes from baseline to end of study averaged 2.9 episodes/24 hours with solifenacin 5 mg, 3.4 episodes/24 hours with solifenacin 10 mg, and 2.0 episodes/24 hours with placebo (P <.001 for both doses). Treatment effects (active vs placebo) were 1.4 and 1.48 episodes for the solifenacin 5-mg and solifenacin 10-mg treatment arms, respectively, and both differences were statistically significant (P <.001). Additionally, 62% of solifenacin 5-mg patients and 66% of solifenacin 10-mg patients reported that urgency episodes were reduced by at least 50% at study endpoint, compared with 44% of the placebo group. Subset analysis revealed that solifenacin was equally effective in reducing urgency episodes in women and men. Women treated with 5 mg solifenacin reported a reduction of 3.0 episodes of urgency from study baseline to endpoint. That difference, as well as the reduction achieved with 10 mg solifenacin, was statistically significant compared with placebo (P <.001). In an analysis involving more than 2800 symptomatic OAB patients, treatment with solifenacin was associated with statistically significant reductions in episodes of urgency. Solifenacin appears to be the first antimuscarinic agent to achieve statistically significant reductions in quantified episodes of urgency across multiple trials. This finding was confirmed when changes in urgency episodes were evaluated in the subgroup of women. NOCTURNAL POLYURIA IN WOMEN WITH NOCTURIA AND OVERACTIVE BLADDER SYMPTOMS Based on a poster presented by Drake NL, Flynn MK, Romero AA, Weidner AC, Amundsen CL Duke University Medical Center, Durham, North Carolina The prevalence of nocturnal polyuria increases with age in men complaining of nocturia and over- Advanced Studies in Medicine S861
3 active bladder (OAB) symptoms. Our objective was to determine the prevalence of nocturnal polyuria in a group of women complaining of nocturia and OAB symptoms. Additionally, we sought to determine whether the risk of nocturnal polyuria increases in women aged 60 years and older and to describe the impact of the symptoms on quality of life. Participants were women presenting to a urogynecology clinic with complaints of nocturia and OAB symptoms. Patients completed a 3-day voiding diary, the Nordic sleep questionnaire, the urinary distress inventory (UDI-6), and a nocturia distress visual log. The 24-hour urine production, nighttime urine production, and functional bladder capacity were determined from the bladder diary, and the nocturnal index was calculated by dividing nighttime urine production by functional bladder capacity. Nocturnal polyuria was defined as production of more than 33% of urine volume during an 8-hour sleep cycle. Patients were divided into 2 age groups: under age 60 years and 60+ years. Additionally, patients were subdivided into groups with and without nocturnal polyuria for further analysis. A total of 55 participants completed the study. Nine were younger than 60 years of age, and the remaining 46 were 60 years of age or older. None of the younger patients met the definition of nocturnal polyuria, whereas 31 of 46 older patients did demonstrate nocturnal polyuria (P Table. Nocturnal Polyuria by Age Age (yrs) < P value (n = 9) (n = 46) Nocturnal polyuria 0 31 <.001 Median number of nighttime voids hour urine output (median, ml) Maximum bladder capacity (median, ml) Nocturnal index UDI Nocturnal distress score 8 8 Insomnia score Sleepiness score 7 8 UDI-6 = urinary distress inventory. <.001, Table). The age groups did not differ with respect to mean values for the UDI-6, nocturnal distress visual log, sleep, and insomnia scores. Moreover, when patients were divided according to whether they had nocturnal polyuria, scores between the groups did not differ for any of the outcomes measures assessed. The 24-hour urine output and maximum bladder capacity do not differ significantly by age in the diagnosis of nocturnal polyuria. In the community-dwelling population, women aged 60 years and older had an increased rate of nocturnal polyuria. The frequency/volume diary is a useful tool for the diagnosis of nocturnal polyuria. BOTULINUM A TOXIN (BOTOX) INJECTION FOR THE TREATMENT OF REFRACTORY OVERACTIVE BLADDER Based on a poster presented by Abdelmalak JB, Rackley RR, Vasavada SP, Ghoniem G, El-Azab AS, Moy L Cleveland Clinic Foundation, Cleveland, Ohio Botulinum A toxin (Botox) is a presynaptic inhibitor of acetylcholine release and an accepted treatment for skeletal muscle spasticity and focal smooth muscle contraction. Botox has also been injected into the detrusor muscle for treatment of urinary incontinence due to neurogenic detrusor overactivity. 1 The investigators report their results of a pilot study of Botox to treat patients with refractory overactive bladder (OAB). Eighteen patients with refractory OAB have been enrolled. The mean age of the patients is 57 years. Pretreatment evaluation consists of medical history, physical examination, urine and blood studies for infection, ultrasound of the upper urinary tract to rule out renal obstruction, and urodynamics and bladder ultrasound. The injection technique begins with the bladder filled with 100 ml of 2% lidocaine, which remains in the bladder for 20 minutes. Under cystoscopic visualization, the 300 U of Botox is injected into 30 sites in the detrusor muscle (10 U/0.1 ml/site). Patients have to complete a 3-day voiding diary, bladder perception (OABq) and quality of life questionnaires (Urinary Distress S862 Vol. 4 (10C) November 2004
4 Table. Changes in [values] from Baseline to 6 Months 3-Month Follow-up 6-Month Follow-up Baseline Mean P value Mean P value Value Value % changes Value % changes F L U BP IIQ UDI F = frequency; L = leaks; U = urgency; BP = bladder perception; IIQ7 = Incontinence Impact Quesionnaire; UDI6 = Urinary Distress Inventory. Inventory-6 and Incontinence Impact Questionnaire- 7) before injection and at 3 and 6 months after injection. All patients tolerated the procedure very well. At a 3-month follow-up, there was improvement in most outcomes of 20% to 40%, which is statistically significant. At 6 months follow-up, the improvement was not as durable (Table). There were no short- or longterm complications except blood in urine after the injection, which is self-limited. Botox injected into the detrusor muscle is safe and effective for treatment of refractory OAB. The treatment is reversible, less invasive, and less expensive compared with other options. On the basis of the results of this pilot study, a multicenter, prospective study with long-term follow-up is warranted. REFERENCE 1. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-a toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45(4): DO CHRONIC CONDITIONS AND PSYCHOLOGICAL HEALTH PLAY A ROLE IN URINARY INCONTINENCE? Based on a poster presented by Romero AA, Jamison MG, Weidner AC, Amundsen CL Duke University Medical Center, Durham, North Carolina Urinary incontinence affects a substantial proportion of women across all age groups. Incontinence may be related to poor health and impairments in mental and physical functioning. Factors known to be associated with an increased prevalence of urinary incontinence include obesity, gynecologic operations, chronic respiratory illness, constipation, parity, and jobs involving heavy lifting. Studies evaluating individuals with urinary incontinence and associated functional loss have demonstrated that women with incontinence and functional loss secondary to incontinence are more likely to have more psychological distress. Resilience can be defined as the tendency to rebound, recoil or to spring back, the power of recovery. The benchmark of resilient behavior is the ability to maintain competent functioning despite interfering emotionality. The objective of this study was to compare physical and psychological health characteristics among 3 age groups of women with and without urinary incontinence and to evaluate the effects of incontinence on physical functioning. The Midlife Development in the United States Survey, a nationally representative random sample of 1735 women aged 25 to 75 years, was used. The survey evaluates more than 2000 variables. The Interactive Activity of Daily Living (iadl) assessed daily functioning such as limitations to climb stairs, bend or kneel, walk, or perform moderate activity. Combining questions on control over life, satisfaction with self, solution of life s problems, and contribution to others, a score measuring resilience, an overall measure of psychological health, was created. Women with and without urinary incontinence across 3 age groups (25 to 39 years, 40 to 59, and 60 to 75 years) were compared. The researchers further compared women without urinary incontinence or chronic conditions with women with urinary incontinence and individual chronic medical conditions. Advanced Studies in Medicine S863
5 Table. Number of Chronic Conditions Age (yrs) UI No UI P value < < <.01 UI = urinary incontinence. The prevalence of urinary incontinence was 15.1%, 36.3%, and 44% among the young, middle, and older groups, respectively. An evaluation of risk factors for urinary incontinence showed that obesity was the only factor that predicted increased risk across all age groups. Chronic lung disease, back conditions, chronic sleeping problems, hysterectomy, and parity of greater than 1 demonstrated inconsistent effects across age groups, but each factor had some effect on at least one age group. Across all age groups, women with incontinence had significantly more chronic conditions compared to women without (Table). A comparison of women with and without urinary incontinence revealed more health-related limitations on daily functioning in women with urinary incontinence. The iadl scores demonstrated significantly greater limitation among incontinent women across all age groups with respect to climbing stairs, bending, or kneeling. Comparison of resilience among women with and without incontinence showed significantly lower scores with respect to solution of life problems for all age groups of women with incontinence. Women with urinary incontinence have significantly more chronic conditions than women without urinary incontinence. Obesity is a risk factor for urinary incontinence across all age groups. Additional risk factors are hysterectomy, chronic sleeping problems, parity, and sciatica or backache. Women with incontinence demonstrated more health-related limitations on daily functioning and decreased resilience, especially in solving life problems. THE EFFECTS OF DARIFENACIN ON THE REDUCTION OF INCONTINENCE EPISODES IN PATIENTS WITH OVERACTIVE BLADDER Based on a presentation by Hill S Queen s Park Hospital, Blackburn, United Kingdom Overactive bladder (OAB) is a particularly prevalent condition among older populations. The unpredictability of urge incontinence can cause considerable distress that impairs quality of life. Darifenacin is a highly selective muscarinic M3 receptor antagonist developed for treatment of OAB. Because of the selectivity of the agent, the likelihood of tolerability and safety problems due to non-m3 blockade is reduced. A multicenter, double-blind, placebo-controlled trial evaluated darifenacin in patients with symptomatic OAB, with a particular emphasis on reducing episodes of incontinence. The trial involved adults with OAB symptoms for at least 6 months, including 5 or more urge incontinence episodes weekly, micturition frequency of 8 or more voids daily, and one or more urgency episodes daily. The patients were randomized to placebo or to one of 2 doses of darifenacin (7.5 mg or 15 mg, both once daily) and followed for 12 weeks. The primary endpoint was the change from baseline to 12 weeks in the number of weekly incontinence episodes. Efficacy was evaluated by means of a validated electronic diary. Tolerability and safety were evaluated by means of adverse event reports, laboratory assessment, vital signs, and withdrawal from the study. The trial involved 324 patients aged 21 to 88 years, 85% of whom were female and 27.2% of whom were 65 years of age or older. Median number of incontinence episodes weekly ranged between 13.7 and 17.3 in the 3 treatment groups. Overall, 293 (90.4%) patients completed the study. The principal reasons for discontinuation were adverse events and withdrawal of consent. Compared with placebo, both doses of darifenacin significantly reduced weekly episodes of incontinence. The 7.5-mg dose of darifenacin resulted in a median difference of 2.8 episodes versus placebo at 12 weeks (P =.007), and the difference was 4.3 episodes for the 15-mg dose (P <.001). Significant differences in favor of darifenacin were evident within 2 weeks after begin- S864 Vol. 4 (10C) November 2004
6 ning treatment. Significantly more darifenacin-treated patients achieved 50% or greater, 70% or greater, and 90% or greater reductions in incontinence episodes compared with placebo. The most common treatment-related adverse event was dry mouth, which occurred in 23.1% and 39.3% of patients treated with 7.5 mg and 15 mg of darifenacin, respectively. Constipation occurred in 15.7% of patients receiving 7.5 mg darifenacin and 25.2% of the 15-mg group. Few patients discontinued because of adverse events (0% with 7.5 mg darifenacin, 0.9% with 15 mg darifenacin). Treatment-related central nervous system adverse events occurred in 0.9% of the darifenacin 7.5-mg group and 3.7% of the 15-mg group. Treatmentrelated cardiovascular events occurred in 2.8% of the darifenacin 7.5-mg group and in 0.9% of patients receiving 15 mg. No serious adverse events or clinically relevant laboratory changes occurred during the trial. Darifenacin at once-daily doses of 7.5 mg and 15 mg significantly reduced the frequency of urge incontinence and allowed a substantial proportion of patients a level of continence approaching normal ( 90%). Darifenacin had a favorable tolerability and safety profile. The findings indicate that darifenacin represents a promising approach to the treatment of OAB. Advanced Studies in Medicine S865
7 NOTES S866 Vol. 4 (10C) November 2004
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging
Urinary Incontinence in Women: Never an Acceptable Consequence of Aging Catherine A. Matthews, MD Associate Professor Chief, Urogynecology and Pelvic Reconstructive Surgery University of North Carolina,
More informationStudy No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122
Page 13 of 122 3 SYNOPSIS Title of study: (International) Study No: A randomized, double-blind, parallel group, proof-of-concept study of in comparison with placebo and tolterodine in patients with symptomatic
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationSubjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented Goals the Search for Value
european urology supplements 6 (2007) 438 443 available at www.sciencedirect.com journal homepage: www.europeanurology.com Subjective Measures of Efficacy: Quality of Life, Patient Satisfaction and Patient-Oriented
More informationInnovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders
TNe 10 Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders Stuart B. Bauer, MD President, ICCS Department of Urology Children s Hospital Boston Professor of Urology Harvard
More informationAnticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Página 1 de 6 PubMed darifenacin vs solifenacin Display Settings:, Sorted by Recently Added Results: 5 1. Int Urogynecol J. 2013 Oct 25. [Epub ahead of print] Anticholinergic medication use for female
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationTREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH
TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH CONTENTS Overactive bladder (OAB) Treatment of OAB Beta-3 adrenoceptor agonist (Betmiga ) - Panacea? LASER treatment - a flash in the pan or the
More informationManagement of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals
Management of OAB Lynsey McHugh Consultant Urological Surgeon Lancashire Teaching Hospitals Summary Physiology Epidemiology Definitions NICE guidelines Evaluation Conservative management Medical management
More informationOveractive Bladder (OAB) and Quality of Life
Overactive Bladder (OAB) and Quality of Life Dr. Byron Wong MBBS (Sydney), FRCSEd, FRCSEd (Urol), FCSHK, FHKAM (Surgery) Specialist in Urology Central Urology Clinic Hong Kong Continence Society Annual
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationSupplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI
Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI Authors: Tatyana A. Shamliyan, MD, MS Senior Director, Evidence-Based Medicine Quality Assurance Elsevier 1600 JFK Blvd,
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION MIRABEGRON (Myrbetriq Astellas Pharma Canada Inc.) Indication: Overactive Bladder Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that mirabegron be listed
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationThe International Continence Society
REPORTS Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in Adults Richard G. Roberts, MD, JD; Alan D. Garely, MD; and Tamara Bavendam, MD Abstract This article evaluates
More informationUrinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital
Urinary Incontinence Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital Affects women of all ages Impacts physical, psychological & social wellbeing Impact on families & carers Costs the
More informationDiagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. TARGET POPULATION Eligibility Decidable (Y or N) Inclusion Criterion non-neurogenic OAB Exclusion Criterion
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION PROPIVERINE HYDROCHLORIDE (Mictoryl/Mictoryl Pediatric Duchesnay Inc.) Indication: Overactive bladder This document was originally issued on April
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationSolifenacin significantly improves all symptoms of overactive bladder syndrome
REVIEW doi: 10.1111/j.1742-1241.2006.01067.x Solifenacin significantly improves all symptoms of overactive bladder syndrome C. R. CHAPPLE, 1 L. CARDOZO, 2 W. D. STEERS, 3 F. E. GOVIER 4 1 Department of
More informationEffect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder
www.kjurology.org DOI:10.4111/kju.2011.52.6.396 Voiding Dysfunction Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder Young Kook Han, Won Ki Lee, Seong Ho Lee, Dae
More informationDrug Class Review on Urinary Incontinence Drugs
Drug Class Review on Urinary Incontinence Drugs FINAL REPORT February 2003 Marian S. McDonagh, PharmD Produced by Oregon Evidence-based Practice Center Oregon Health & Science University 3181 SW Sam Jackson
More informationThe Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis
European Urology European Urology 48 (2005) 5 26 ReviewöOveractive Bladder The Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis Christopher Chapple a, *,
More informationUrogynecology Office. Can You Hold? An Update on the Treatment of OAB. Can You Hold? Urogynecology Office
Urogynecology Office Urogynecology Office Can You Hold? An Update on the Treatment of OAB Can You Hold? Karen Noblett, MD Professor and Chair Department of OB/GYN University of California, Riverside Disclosures
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationDrugs for Overactive Bladder (OAB)
ril 2014 Drugs for Overactive Bladder (OAB) FINAL CONSOLIDATED COMPREHENSIVE RESEARCH PLAN July 2015 FINAL COMPREHENSIVE RESEARCH PLAN 2 A. Introduction The objective of the drug class review on drugs
More informationTuesday 24 June Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart
Tuesday 24 June 10.30 11.30 Poster Session 1: Voiding Dysfunction Chairmen: C. Chapple and L. Stewart P001 Can oral antibiotic prophylaxis reduce the rate of infection after conventional urodynamic studies?
More informationDisclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.
Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric
More informationOveractive Bladder beyond antimuscarinics
Overactive Bladder beyond antimuscarinics Marcus Drake Bristol Urological Institute Conflicts of interest; Allergan, AMS, Astellas, Ferring, Pfizer Getting the diagnosis right Improving treatment Improving
More informationPhiladelphia College of Osteopathic Medicine. Victoria J. Kopec Philadelphia College of Osteopathic Medicine,
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Does Treatment With OnabotulinumtoxinA
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationHow to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina
Reviews How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxina Mikolaj Przydacz A F, Tomasz Golabek A,E,F, Piotr Chlosta A,E,F Department of Urology, Jagiellonian
More informationDRUG FORECAST. Select Conditions of the Lower Urinary Tract
Transdermal Oxybutynin: Novel Drug Delivery for Overactive Bladder Vitalina Rozenfeld, PharmD, BCPS, Stanley Zaslau, MD, Kathleen New Geissel, PharmD, David Lucas, PhD, and Lili Babazadeh, PharmD INTRODUCTION
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Urinary incontinence in women: the management of urinary incontinence in women 1.1 Short title Urinary incontinence in women
More informationOveractive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based
Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based upon a medical history, and includes a focused physical exam (abdominal, neurological, pelvic in females and
More informationPresentation Goals 4/14/2015. Pharmacology for Urinary Incontinence in Women. Medications Review anti muscarinic medications Focus on newer meds
Presentation Goals Pharmacology for Urinary Incontinence in Women Medications Review anti muscarinic medications Focus on newer meds Introduce beta adrenergic medications Current Concepts in Drug Therapy
More informationClinical guidelines for overactive bladder
International Journal of Urology (2009) 16, 126 142 doi: 10.1111/j.1442-2042.2008.02177.x Guidelines Clinical guidelines for overactive bladder Osamu Yamaguchi, 1 Osamu Nishizawa, 2 Masayuki Takeda, 3
More informationThe Management of Overactive Bladder Syndrome with Antimuscarinic Drugs
The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs Author Version Date Consultation Date of Ratification By JPG Shaista Hussain Joint Formulary Pharmacist V2 16.09.2014 Homerton University
More informationOveractive Bladder in Clinical Practice
Overactive Bladder in Clinical Practice Alan J. Wein Christopher Chapple Overactive Bladder in Clinical Practice Authors Alan J. Wein Division of Urology University of Pennsylvania Health System Philadelphia
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationDr Jonathan Evans Paediatric Nephrologist
How do I manage a patient with intractable daytime wetting: Dr Jonathan Evans Paediatric Nephrologist Of 107 children aged 11-12 with day-wetting 91 (85%) were dry at 15-16 yr Swithinbank et al BJU 1998
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationRetrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder
European Urology European Urology 45 (2004) 240 244 Retrospective Analysis of Efficacy and Tolerability of Tolterodine in Children with Overactive Bladder A. Raes a,, P. Hoebeke b, I. Segaert a, E. Van
More informationDrug Class Review on Overactive Bladder Drugs
Drug Class Review on Overactive Bladder Drugs Preliminary Scan Report #1 February 2014 Last Summary Review (June 2013) The Agency for Healthcare Research and Quality has not yet seen or approved this report
More informationTools for Evaluation. Urodynamics Case Studies. Case 1. Evaluation. Case 1. Bladder Diary SUI 19/01/2018
Urodynamics Case Studies Christopher K. Payne, MD Vista Urology & Pelvic Pain Partners Emeritus Professor of Urology, Stanford University Tools for Evaluation Ears, Eyes, and Brain Bladder diary Stress
More informationClinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive Bladder
Advances in Urology Volume 2009, Article ID 328364, 4 pages doi:10.1155/2009/328364 Clinical Study Predictors of Response to Intradetrusor Botulinum Toxin-A Injections in Patients with Idiopathic Overactive
More informationUrinary Incontinence. Lora Keeling and Byron Neale
Urinary Incontinence Lora Keeling and Byron Neale Not life threatening. Introduction But can have a huge impact on quality of life. Two main types of urinary incontinence (UI). Stress UI leakage on effort,
More informationComparison of Side Effects of Tolterodine and Solifenacinsucinate in Patients with Urinary Incontinence
ORIGINAL ARTICLE Comparison of Side Effects of Tolterodine and Solifenacinsucinate in Patients with Urinary Incontinence MARYAM RANA, IRAM MOBUSHER ABSTRACT Background: Overactive bladder syndrome is a
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationParkinson s Disease and Multiple System Atrophy
Parkinson s Disease and Multiple System Atrophy Jalesh N. Panicker MD, FRCP Department of Uro-Neurology National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology Queen Square, London
More informationAccording to the INDICATIONS AND USAGE section of its FDA-approved product labeling (PI):
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Karen L. Walles, M.S. Assistant Director, Regulatory Affairs 3
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationIs There a Best Drug for Overactive Bladder in a Patient with Dementia?
Is There a Best Drug for Overactive Bladder in a Patient with Dementia? Todd Semla, MS, Pharm.D., BCPS, FCCP, AGSF National PBM Clinical Pharmacy Program Manager Mental Health & Geriatrics U.S. Department
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July-August
BRAND NAME Noctiva GENERIC NAME Desmopressin acetate nasal spray MANUFACTURER Serenity Pharmaceuticals DATE OF APPROVAL March 3, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review
More informationEfficacy and Safety of Propiverine in Children with Overactive Bladder
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.275 Pediatric Urology Efficacy and Safety of Propiverine in Children with Overactive Bladder Woo Jung Kim, Dong-Gi Lee 1, Sang Wook Lee 2, Yoon
More informationOutcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder Michael K. Flynn,* Cindy L. Amundsen, MaryAnn Perevich, Fan Liu and George D. Webster
More information25-Feb-16 MANAGEMENT OF URINARY INCONTINENCE IN WOMEN.
Female Urinary Incontinence: GP resources MANAGEMENT OF URINARY INCONTINENCE IN WOMEN Dr Marcus Carey 20 February 2016 www.thewomens.org.au Clinical Practice Guidelines GP management of female urinary
More informationHospital and Tzu Chi University, Hualien, Taiwan
LUTS (2012) 4, 29 34 ORIGINAL ARTICLE Difficult Urination Does Not Affect the Successful Outcome after 100U OnabotulinumtoxinA Intravesical Injection in Patients with Idiopathic Detrusor Overactivity Yih-Chou
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013 ClinicalTrials.gov ID: NCT00168454 Study Identification Unique Protocol ID: 191622-077 Brief Title: A
More informationNEUROGENIC BLADDER. Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph
NEUROGENIC BLADDER Dr Harriet Grubb Dr Alison Seymour Dr Alexander Joseph OUTLINE Definition Anatomy and physiology of bladder function Types of neurogenic bladder Assessment and management Complications
More informationTHE OVER-ACTIVE BLADDER (OAB)
THE OVER-ACTIVE BLADDER (OAB) Passage of urine is caused by the bladder muscle contracting coordinated with the relaxation of the sphincter muscles, which is controlled by higher centers in the central
More informationURINARY INCONTINENCE. Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara
URINARY INCONTINENCE Urology Division, Surgery Department Medical Faculty, University of Sumatera Utara Definition The involuntary loss of urine May denote a symptom, a sign or a condition Symptom the
More informationClinical Medicine Insights: Urology
Clinical Medicine Insights: Urology original research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Efficacy and Safety of 10 mg Solifenacin Succinate in
More informationOveractive bladder syndrome (OAB)
Service: Urology Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or
More informationEfficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study
doi: 10.1111/j.1742-1241.2008.01898.x ORIGINAL PAPER Efficacy and safety of solifenacin succinate in n patients with overactive bladder: a randomised, prospective, double-blind, multicentre study M.-S.
More informationDrug Class Review Agents for Overactive Bladder
Drug Class Review Agents for Overactive Bladder Final Update 4 Report Evidence Tables March 2009 The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationPosterior Tibial Nerve Stimulation for Voiding Dysfunction
Posterior Tibial Nerve Stimulation for Voiding Dysfunction Corporate Medical Policy File name: Posterior Tibial Nerve Stimulation for Voiding Dysfunction File code: UM.NS.05 Origination: 8/2011 Last Review:
More informationUK Consensus on Bladder Management in MS
Continence Care Forum Annual Conference UK Consensus on Bladder Management in MS Clare J.Fowler National Hospital for Neurology and Neurosurgery & Institute of Neurology, UCL Association of British Neurologists
More informationDrug Class Review Agents for Overactive Bladder
Drug Class Review Agents for Overactive Bladder Final Update 4 Report March 2009 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta290
Mirabegron for treating symptoms of overactive bladder Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta290 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationOveractive bladder. Information for patients from Urogynaecology
Overactive bladder Information for patients from Urogynaecology An overactive bladder (OAB) is a very common problem. It can cause distressing symptoms that are difficult to control. These can include
More informationUrinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies. Dr. Boris Friedman May 2, 2012 OBJECTIVES
Urinary Aspects of Multiple Sclerosis chronic condition with innovative treatment strategies Dr. Boris Friedman May 2, 2012 OBJECTIVES 1) Definition and classification of MS 2) Interventional radiology
More informationUrinary incontinence in women
Urinary incontinence in women Lauren N Wood, 1 Jennifer T Anger 2 1 Cedars-Sinai Medical Center, Department of Surgery, Division of Urology, Los Angeles, CA, USA 2 Urologic Reconstruction, Urodynamics,
More informationUrogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018
Urogynecology in EDS Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018 One in three like me Voiding Issues Frequency/Urgency Urinary Incontinence neurogenic bladder Neurologic supply
More information3/20/10. Prevalence of OAB Men: 16.0% Women: 16.9% Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Dry. Population (millions) Wet
1 Prevalence of OAB Men: 16.0% Women: 16.9% Stewart WF, et al. World J Urol. 2003;20:327-336. Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Stewart WF, et al. World J Urol. 2003;20:327-336.
More informationManagement of Urinary Incontinence in Older Women. Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital
Management of Urinary Incontinence in Older Women Dr. Cecilia Cheon Department of Obs. & Gyn. Queen Elizabeth Hospital Epidemiology Causes Investigation Treatment Conclusion Elderly Women High prevalence
More informationUrinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives
Urinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives Arun Sahai PhD, FRCS (Urol) Consultant Urological Surgeon & Honorary Senior Lecturer Guy s Hospital
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationDiagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline.
Diagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline. IDENTITY Citation Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr,
More informationOVERACTIVE BLADDER (OAB)
OVERACTIVE BLADDER (OAB) Ms Taryn Hallam Alana Health Care for Women Women s Health Training Associates OVERACTIVE BLADDER The most misdiagnosed and misunderstood of all the urinary disorders. Problem???
More informationDescription. Section: Surgery Effective Date: October 15, 2014 Subsection: Surgery Original Policy Date: December 6, 2012 Subject:
Last Review Status/Date: September 2014 Page: 1 of 10 Description Posterior tibial nerve stimulation (PTNS) is a technique of electrical neuromodulation used for treating voiding dysfunction. The tibial
More informationURGE MOTOR INCONTINENCE
URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus
More informationBotulinum Toxin Injection for OAB: Indications & Technique
Classification of LUTS Botulinum Toxin Injection for OAB: Indications & Technique Sherif Mourad, MD Professor of Urology, Ain Shams University General Secretary of International Continence President of
More informationMedical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011
Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011 Treatment, Urinary Stress Incontinence, Transurethral Effective Date: 01/01/2012 Document: ARB0359 Revision Date: Code(s): 53860 Transurethral
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationDiagnosis and Treatment of Urinary Incontinence. Urinary Incontinence
Diagnosis and Treatment of Urinary Incontinence Leslee L. Subak, MD Professor Obstetrics, Gynecology & RS Epidemiology, Urology University of California, San Francisco Urinary Incontinence Common - 25%
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Posterior Tibial Nerve Stimulation Page 1 of 11 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Posterior Tibial Nerve Stimulation Professional Institutional
More informationEfficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study
LUTS () 3, 36 4 ORIGINAL ARTICLE Efficacy and Safety of Propiverine and Solifenacin for the Treatment of Female Patients with Overactive Bladder: A Crossover Study Naoki WADA, Masaki WATANABE, Masafumi
More informationIndividual Study Table Referring to Part of the Dossier. Volume: Page:
1 SYNOPSIS (CR002878) Title of Study: The effect of on vasomotor symptoms in healthy postmenopausal women: a double-blind placebo controlled pilot study Investigators: Multiple, see Section 4, Investigators
More informationResults The Authors. BJU Int 2017; 120:
Functional Urology Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study) Sender Herschorn*, Christopher
More informationEvaluation & Management of Overactive Bladder
Evaluation & Management of Overactive Bladder Disclosures/Conflict of Interest/Bias I have no financial relationship with any of the companies that produce the products I m about to discuss I have no conflicts
More informationLa vescica iperattiva: dalla diagnosi ai nuovi approcci terapeutici
La Prostata nel Mirino Napoli, 1 dicembre 2016 La vescica iperattiva: dalla diagnosi ai nuovi approcci terapeutici Giorgio Annoni Cattedra e Scuola di Specializzazione in Geriatria Università degli Studi
More informationIncontinence; Lets talk about it. Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery
Incontinence; Lets talk about it Karanvir Virk M.D. Minimally Invasive and Pelvic Reconstructive Surgery Select the most appropriate subtitle for this talk A: Bladders gone wild! B: There s no such thing
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationD-MANNOSE, CRANBERRY AND VITAMIN C (CYSTOMAN 100MG) ARE EFFECTIVE IN PREVENTING URINARY TRACT INFECTIONS IN MULTIPLE SCLEROSIS SUBJECTS.
D-MANNOSE, CRANBERRY AND VITAMIN C (CYSTOMAN 100MG) ARE EFFECTIVE IN PREVENTING URINARY TRACT INFECTIONS IN MULTIPLE SCLEROSIS SUBJECTS. Maria Laura Lopes De Carvalho, MD Guido Francavilla, MD Roberta
More information